Committee hears divergent views on bill to cap some drug prices at Medicare’s negotiated rates

Assemblymember Venetia Considine introduced Assembly Bill 2 59, proposing that for a limited set of high‑cost, non‑competitive drugs the price paid in Nevada not exceed the ‘‘maximum fair price’’ negotiated by Medicare under the federal Inflation Reduction Act. Considine said the measure is an effort to extend negotiated Medicare prices to non‑Medicare patients for a small set of drugs beginning with 10 drugs in 2026 and a larger set in subsequent years.

‘‘When do we stand up to bullies?’’ Considine asked the committee, framing the bill as a response to rapidly rising prices that force some Nevadans to choose between medication and basic needs. She said the proposal is modeled on Medicare negotiation under the Inflation Reduction Act and would not be a blanket price‑setting scheme but would use prices already negotiated federally.

Supporters — including patient advocates, health‑care advocates and affected residents — told the committee the bill would produce substantial savings for people who pay out of pocket or whose plans do not benefit from federal negotiation. Several witnesses described life‑threatening examples: a mother who said she paid prices for insulin that exceeded her mortgage payment after her child’s type‑1 diabetes diagnosis, and other witnesses who described family members rationing or foregoing medication because of cost.

Opponents included pharmacy groups, hospitals, wholesalers and several industry associations, which argued the measure as drafted could create operational and legal problems that would harm patient access. Opposition testimony raised three recurring concerns: how the cap would interact with existing purchase and reimbursement flows (wholesalers, distributors, group purchasing organizations and national contracts), uncertainty about how pharmacies and hospitals would be reimbursed if acquisition costs exceed the statutory cap, and whether the state‑level cap could trigger interstate commerce or supply issues.

Pharmacy witnesses said the federal implementation under Medicare does not require pharmacies to buy directly at the negotiated maximum fair price; instead, federal rules rely on a reconciliation/rebate mechanism that is not replicated for non‑Medicare purchasers. Adam Porth, vice president of pharmacy at Renown Health and representing the Nevada Society of Health System Pharmacists, said the bill omits the federal reconciliation mechanism and is silent on how to treat transactions under programs such as the federal 340B program. He warned the difference in purchasing streams could create a separate Nevada purchasing line that manufacturers, wholesalers and pharmacies would need to support.

Trade groups and manufacturers also warned that pharmacies and hospitals could be forced to absorb losses or stop stocking certain medicines if acquisition costs exceed allowable reimbursement. Jennifer Lanahan of the Nevada Pharmacy Alliance urged amendments to ensure pharmacy reimbursement covers acquisition cost plus a reasonable dispensing fee and to exempt pharmacies from legal liability related to pricing decisions. The Healthcare Distribution Alliance and wholesalers said contracts and regional purchasing arrangements would be disrupted by a state‑level price cap.

Several labor and beneficiary groups urged the committee to pass the bill. New Day Nevada, the Culinary Health Fund (neutral but engaged on amendments), firefighters, and patient advocates said capping prices at Medicare negotiated levels would quickly reduce the out‑of‑pocket burden for many Nevadans. Supporters cited projected savings of 25–60% on selected drugs and said the Inflation Reduction Act already produced savings for Medicare beneficiaries.

Committee members asked for empirical estimates and implementation details. The sponsor said she provided documents comparing list prices with negotiated Medicare prices and that projected savings could be thousands of dollars per family for affected medicines. Witnesses opposing the bill urged the committee to address pharmacy reimbursement, the 340B safety‑net program, wholesale distribution contracts and potential unintended consequences before advancing the measure.

The committee took testimony from a broad set of stakeholders and closed the hearing without a vote. The sponsor said she would continue to work with opponents and neutral stakeholders to address technical and operational concerns.